Markets

Adamas Pharmaceuticals Hits 80-Plus Relative Strength Rating Benchmark

Shutterstock photo

One important metric to look for in a stock is an 80 or higher Relative Strength Rating . Adamas Pharmaceuticals ( ADMS ) just hit that mark, with a jump from 79 to 84 Friday.

[ibd-display-video id=449433 width=50 float=left autostart=true] IBD's proprietary RS Rating tracks market leadership by using a 1 (worst) to 99 (best) score that indicates how a stock's price action over the trailing 52 weeks matches up against the rest of the market.

Over 100 years of market history shows that the stocks that go on to make the biggest gains tend to have an RS Rating north of 80 as they begin their biggest runs.

Looking For The Best Stocks To Buy And Watch? Start Here

Adamas Pharmaceuticals is now considered extended and out of buy range after clearing a 19.60 buy point in a first-stage consolidation . See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line.

The company posted negative growth for both the top and bottom lines last quarter.

The company holds the No. 168 rank among its peers in the Medical-Biomed/Biotech industry group. Celgene ( CELG ), Corcept Therapeutics ( CORT ) and Ligand Pharmaceuticals ( LGND ) are among the top 5 highly rated stocks within the group.

RELATED:

Biotech And Pharmaceutical Industry And Stock News

Which Stocks Are Showing Rising Relative Strength?

Why Should You Use IBD's Relative Strength Rating?

How Relative Strength Line Can Help You Judge A Stock

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

CELG CORT LGND ADMS

Other Topics

Stocks

Latest Markets Videos